Non-UV Light Treatment Reduces Coronavirus Viral Load

North Carolina-based EmitBio Inc. announced on February 17, 2021, significant efficacy results from its Phase I/II clinical trial conducted with an investigational treatment device for COVID-19 that directs precise wavelengths of safe, visible light targeted to the back of the throat and surrounding tissues.

The EmitBio self-treatment device achieved clinically and statistically significant results in reducing SARS-CoV-2 viral load and accelerated time to symptom resolution in adults with COVID-19. EmitBio is a rechargeable, handheld device that bathes the back of the throat with safe, non-UV light during a five-minute treatment.

“The ability to show statistical significance on both viral load and symptom endpoints with this sample size is a direct illustration of just how powerful our light treatment device can be,” stated Nate Stasko, Ph.D., Chief Scientific Officer at EmitBio, in a related press statement.

Due to these statistically significant results and findings, the company concluded its Phase I/II trial early and initiated activities to prepare additional COVID-19 trials in other populations. The clinical trial results and the results from a Phase I safety study in healthy volunteers have been submitted as part of a comprehensive package to the FDA requesting Emergency Use Authorization.

Salivary viral load is a powerful predictive indicator for disease progression to more severe manifestations of COVID-19, says the company. Researchers at Yale University and other major institutions recently published evidence demonstrating a clear-cut relationship between SARS-CoV-2 viral load measured in saliva and COVID-19 symptom severity.

EmitBio Inc. is a life science company using the precise delivery of safe, visible light to stimulate, heal and protect the body.